Fisetin for Alzheimer's Disease

Also known as: 3,3',4',7-Tetrahydroxyflavone

Fisetin is a potent senolytic and neuroprotective flavonoid that targets cellular senescence driving AD neurodegeneration.

Mechanism of Action

Fisetin selectively eliminates senescent cells through PI3K/Akt/mTOR pathway modulation. It activates Nrf2 antioxidant defense, inhibits GSK3β to reduce tau phosphorylation, promotes neurogenesis through ERK signaling, and maintains glutathione levels.

General mechanism: Bioactive flavonoid. Senolytic (PI3K/Akt/mTOR), Nrf2 activator, GSK3β inhibitor, anti-inflammatory, pro-apoptotic in cancer cells.

Current Evidence

AFFIRM trial studying fisetin for Alzheimer's (Phase II). Preclinical models show cognitive improvement and reduced neuroinflammation. Senolytic effects confirmed in aged mice with improved cognitive function.

Clinical Status: Phase II (AFFIRM trial). Available as supplement. Senolytic trials ongoing.

Safety Profile

Very safe. Low oral bioavailability. Liposomal formulations being developed. No significant side effects.

Key Research Questions

View glossary entry →

← Back to Alzheimer's Disease Research